الفهرس 
EPIDEMIOLOGY AND RISK FACTORSOnly 14 pages are availabe for public view
 |  | from | 32 |  |  |
| | | from | 32 | | |
Abstract
L
ung cancer is one of the commonest and most lethal cancers throughout the world. Among the subtypes of lung cancer, non-small cell lung cancer (NSCLC) is the most prevalent, accounting for 85% of all new cases. The epidemiological and pathological profile varies among different ethnicities and geographical regions.
While there have been advances in therapeutic options, a significant unmet medical need remains. There have been small gains in NSCLC survival rates; however, the significance of these gains and the benefits to patients with a variety of characteristics are unclear.
The aim of the study was to analyze the current clinico-pathological profile and factors affecting survival of non small cell lung cancer patients at the department of Clinical Oncology and Nuclear medicine in Ain Shams University hospitals.
Data from records of 195 pathologically confirmed non small cell lung cancer cases were available for clinicopathological analysis during the study period.
The mean age at diagnosis of the study population was 59 years, Male to female ratio was 3.6:1, 71.2% of cases were current or x-smokers, majority of reported cases were living in urban areas, 44.6% of patients had ECOG performance status 1, 41% of patients gave history of medical co morbidity such as diabetes mellitus, hepatitis B or C viral infection or hypertension.
The most common symptom at presentation was dyspnea and right upper lobe was the most common tumour site. Adenocarcinoma was the most common histological subtype representing 62% of cases. Most common stage at diagnosis was stage IV (56.4%) and the most common site of metastasis was bones.
Only 6% of patients underwent surgical excision, 7% of patients received CCRT and 5.6% received sequential chemotherapy and 3D conformal radiotherapy while 35% of patients received palliative chemotherapy as the primary management and Palliative radiotherapy was received in 43.5% of patients at different points of their treatment.
No management was received in 35% of cases due to various reasons, like poor PS, significant co morbidities, logistics and patient’s preferences.
Median overall survival was 9 months and median progression free survival was 7 months.
Statistically significant improvement in overall survival rate and progression free survival rate was found in the following groups: female sex, PS 1 or 2, never smokers, grade II tumors, lower tumor size, less lymph nodal stations involvement, lower stage at diagnosis, single versus multiple metastatic sites and response to definitive treatment.
As regard pathological subtypes, adenocarcinoma was associated with better overall survival rates whereas squamous cell carcinoma was associated with better progression free survival rates.